IAM-K1
Breast cancer, ovarian cancer, and other solid tumors
PreclinicalActive
Key Facts
Indication
Breast cancer, ovarian cancer, and other solid tumors
Phase
Preclinical
Status
Active
Company
About Iambic Therapeutics
Iambic Therapeutics is a private, clinical-stage biotech leveraging a proprietary, integrated AI and high-throughput experimentation platform to accelerate drug discovery. Its core technologies, the Enchant multimodal transformer and NeuralPLexer for protein-ligand structure prediction, are designed to overcome key bottlenecks in preclinical research. The company has advanced its lead asset, IAM1363, into Phase 1b studies for HER2-driven cancers and has established a strategic collaboration with Takeda, positioning it as a player in the AI-driven drug discovery space with both an internal pipeline and a platform partnership model.
View full company profile